Expression levels of STAT3, and protein levels of IL‑6 and sPD‑L1 in different pathological characteristics of endometrial adenocarcinomas

Ma,Chunxing; He,Ying; Wang,Jing; Zhang,Juan; Hou,Xiaoxue; Wang,Sisi; Chen,Lihua; Shu,Lisha

doi:10.3892/ol.2025.14901

Expression levels of STAT3, and protein levels of IL‑6 and sPD‑L1 in different pathological characteristics of endometrial adenocarcinomas

Authors:
- Chunxing Ma
- Ying He
- Jing Wang
- Juan Zhang
- Xiaoxue Hou
- Sisi Wang
- Lihua Chen
- Lisha Shu
View Affiliations

Affiliations: Department of Gynecology and Obstetrics, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei 075000, P.R. China
Published online on: January 23, 2025 https://doi.org/10.3892/ol.2025.14901
Article Number: 156
Copyright: © Ma et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Endometrial cancer is a common type of cancer in women, with endometrial adenocarcinoma (EA) being the most common type. Monitoring the expression levels of signal transducer and activator of transcription 3 (STAT3), the protein levels of interleukin 6 (IL‑6) and soluble programmed death ligand 1 (sPD‑L1), and their differences in patients with various pathological characteristics is beneficial for accurately evaluating the disease stage and differentiation degree of patients in clinical practice. The aim of the present study was to assess the expression levels of STAT3, and the protein levels of IL‑6 and sPD‑L1 in EA. In the present retrospective study, data were retrieved from the medical records of 137 patients with EA who received surgical treatment at The First Affiliated Hospital of Hebei North University from January 2017 to December 2022. Of the 137 cases, 90 met the inclusion criteria. The patients with EA were matched with a cohort of 30 patients with atypical endometrial hyperplasia in a ratio of 3:1. Among the 90 patients with EA, 30 patients with well‑differentiated EA were matched with 30 patients with moderately differentiated EA and 30 patients with poorly differentiated EA in a 1:1:1 ratio. Expression level of STAT3, and protein levels of IL‑6 and sPD‑L1 were recorded preoperatively and compared between patients with different pathological characteristics [such as differentiation degree, disease stage, depth of myometrial invasion and lymph node metastasis (LNM)] and prognosis. Levels of IL‑6, STAT3 and sPD‑L1 in the observation group were significantly higher compared with the control group (P<0.001). Additionally, there were significant differences in IL‑6, STAT3 and sPD‑L1 levels between patients with different differentiation degrees, disease stages, myometrial invasion and LNM (P<0.001). The increase in IL‑6, STAT3 and sPD‑L1 levels were significantly associated with the decrease in the differentiation degree and the increase in the disease stage, depth of myometrial invasion and LNM (P<0.001). IL‑6, STAT3 and sPD‑L1 levels in patients with a poor prognosis were significantly higher compared with patients with good prognoses (P<0.001). Overall, the expression levels of STAT3, and the protein levels of IL‑6 and sPD‑L1 were increased in patients with EA compared with in those without EA, and their increase is associated with the pathological characteristics of the disease. The levels of these indices may be detected in clinical practices to evaluate the disease and predict the prognosis.

View Figures

View References

1	World Cancer Research Fund, . Endometrial Cancer Statistics. Available from:. https://www.wcrf.org/preventing-cancer/cancer-statistics/endometrial-cancer-statistics/December 22–2024
2	Jarboe EA and Mutter GL: Endometrial intraepithelial neoplasia. Semin Diagn Pathol. 27:215–225. 2010. View Article : Google Scholar : PubMed/NCBI
3	Terzic M, Aimagambetova G, Kunz J, Bapayeva G, Aitbayeva B, Terzic S and Laganà AS: Molecular basis of endometriosis and endometrial cancer: Current knowledge and future perspectives. Int J Mol Sci. 22:92742021. View Article : Google Scholar : PubMed/NCBI
4	Dey DK, Krause D, Rai R, Choudhary S, Dockery LE and Chandra V: The role and participation of immune cells in the endometrial tumor microenvironment. Pharmacol Ther. 251:1085262023. View Article : Google Scholar : PubMed/NCBI
5	Wang SE, Viallon V, Lee M, Dimou N, Hamilton F, Biessy C, O'Mara T, Kyrgiou M, Crosbie EJ, Truong T, et al: Circulating inflammatory and immune response proteins and endometrial cancer risk: A nested case-control study and Mendelian randomization analyses. EBioMedicine. 108:1053412024. View Article : Google Scholar : PubMed/NCBI
6	Che Q, Xiao X, Liu M, Lu Y, Dong X and Liu S: IL-6 promotes endometrial cancer cells invasion and migration through signal transducers and activators of transcription 3 signaling pathway. Pathol Res Pract. 215:1523922019. View Article : Google Scholar : PubMed/NCBI
7	Mu QS, Li H, Ye H, Liu YD, Bai J, Yuan L, Wang KJ, Lu KQ and Liu YL: Association of interleukin-6 and CD4+ T cells and two-week prognosis of patients with COVID-19: A predictive role. Eur Rev Med Pharmacol Sci. 27:4782–4791. 2023.PubMed/NCBI
8	Tolomeo M and Cascio A: The multifaced role of STAT3 in cancer and its implication for anticancer therapy. Int J Mol Sci. 22:6032021. View Article : Google Scholar : PubMed/NCBI
9	Jia ZX, Zhang Z, Li Z, Li A, Xie YN, Wu HJ, Yang ZB, Zhang HM and Zhang XM: Anlotinib inhibits the progress of colorectal cancer cells by antagonizing VEGFR/JAK2/STAT3 axis. Eur Rev Med Pharmacol Sci. 25:2331–2343. 2021.PubMed/NCBI
10	Hu X, Li J, Fu M, Zhao X and Wang W: The JAK/STAT signaling pathway: From bench to clinic. Signal Transduct Target Ther. 6:4022021. View Article : Google Scholar : PubMed/NCBI
11	Han Y, Liu D and Li L: PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 10:727–742. 2020.PubMed/NCBI
12	Kim Y, Aiob A, Kim H, Suh DH, Kim K, Kim YB and No JH: Clinical implication of PD-L1 expression in patients with endometrial cancer. Biomedicines. 11:26912023. View Article : Google Scholar : PubMed/NCBI
13	Soslow RA, Tornos C, Park KJ, Malpica A, Matias-Guiu X, Oliva E, Parkash V, Carlson J, McCluggage WG and Gilks CB: Endometrial carcinoma diagnosis: Use of FIGO grading and genomic subcategories in clinical practice: Recommendations of the international society of gynecological pathologists. Int J Gynecol Pathol. 38 (Suppl 1):S64–S74. 2019. View Article : Google Scholar : PubMed/NCBI
14	Vitale SG, Haimovich S, Laganà AS, Alonso L, Di Spiezio Sardo A and Carugno J; From the Global Community of Hysteroscopy Guidelines Committee, : Endometrial polyps. An evidence-based diagnosis and management guide. Eur J Obstet Gynecol Reprod Biol. 260:70–77. 2021. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Yang Y, Song YJ, Nie QB, Wang YF, Zhang M and Mao GS: Correlations of IL-18 and IL-6 gene polymorphisms and expression levels with onset of glioma. Eur Rev Med Pharmacol Sci. 26:1475–1483. 2022.PubMed/NCBI
17	Lu W, He F, Lin Z, Liu S, Tang L, Huang Y and Hu Z: Dysbiosis of the endometrial microbiota and its association with inflammatory cytokines in endometrial cancer. Int J Cancer. 148:1708–1716. 2021. View Article : Google Scholar : PubMed/NCBI
18	Huang Y and Yang N: MicroRNA-20a-5p inhibits epithelial to mesenchymal transition and invasion of endometrial cancer cells by targeting STAT3. Int J Clin Exp Pathol. 11:5715–5724. 2018.PubMed/NCBI
19	Dong P, Xiong Y, Yue J, Xu D, Ihira K, Konno Y, Kobayashi N, Todo Y and Watari H: Long noncoding RNA NEAT1 drives aggressive endometrial cancer progression via miR-361-regulated networks involving STAT3 and tumor microenvironment-related genes. J Exp Clin Cancer Res. 38:2952019. View Article : Google Scholar : PubMed/NCBI
20	Chen J, Huang S, Li H, Li Y, Zeng H, Hu J, Lin Y, Cai H, Deng P, Song T, et al: STAT3 inhibitor BBI608 reduces patient-specific primary cell viability of cervical and endometrial cancer at a clinical-relevant concentration. Clin Transl Oncol. 25:662–672. 2023. View Article : Google Scholar : PubMed/NCBI
21	Chen CL, Hsieh FC, Lieblein JC, Brown J, Chan C, Wallace JA, Cheng G, Hall BM and Lin J: Stat3 activation in human endometrial and cervical cancers. Br J Cancer. 96:591–599. 2007. View Article : Google Scholar : PubMed/NCBI
22	Chu Y, Wang Y, Peng W, Xu L, Liu M, Li J, Hu X, Li Y, Zuo J and Ye Y: STAT3 activation by IL-6 from adipose-derived stem cells promotes endometrial carcinoma proliferation and metastasis. Biochem Biophys Res Commun. 500:626–631. 2018. View Article : Google Scholar : PubMed/NCBI
23	Ma G, Deng Y, Jiang H, Li W, Wu Q and Zhou Q: The prognostic role of programmed cell death-ligand 1 expression in non-small cell lung cancer patients: An updated meta-analysis. Clin Chim Acta. 482:101–107. 2018. View Article : Google Scholar : PubMed/NCBI
24	Cao H, Wang Q, Gao Z, Yu Z, Wu Y and Lu Q: Programmed death-ligand 1 and survival in colorectal cancers: A meta-analysis. Int J Biol Markers. 34:356–363. 2019. View Article : Google Scholar : PubMed/NCBI
25	Zheng Y, Fang YC and Li J: PD-L1 expression levels on tumor cells affect their immunosuppressive activity. Oncol Lett. 18:5399–5407. 2019.PubMed/NCBI
26	Gao K, Shi Q, Gu Y, Yang W, He Y, Lv Z, Ding Y, Cao W, Wang C and Wan X: SPOP mutations promote tumor immune escape in endometrial cancer via the IRF1-PD-L1 axis. Cell Death Differ. 30:475–487. 2023. View Article : Google Scholar : PubMed/NCBI
27	Post CCB, Westermann AM, Bosse T, Creutzberg CL and Kroep JR: PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer. Crit Rev Oncol Hematol. 152:1029732020. View Article : Google Scholar : PubMed/NCBI
28	Wang J, Song T, Zhou S and Kong X: YAP promotes the malignancy of endometrial cancer cells via regulation of IL-6 and IL-11. Mol Med. 25:322019. View Article : Google Scholar : PubMed/NCBI
29	Zhu M, Che Q, Liao Y, Wang H, Wang J, Chen Z, Wang F, Dai C and Wan X: Oncostatin M activates STAT3 to promote endometrial cancer invasion and angiogenesis. Oncol Rep. 34:129–138. 2015. View Article : Google Scholar : PubMed/NCBI
30	Tang Q, Chen Y, Li X, Long S, Shi Y, Yu Y, Wu W, Han L and Wang S: The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol. 13:9644422022. View Article : Google Scholar : PubMed/NCBI
31	Yin S, Guo Y, Wen X, Zeng H and Chen G: Increased expression of PD-L1 in endometrial cancer stem-like cells is regulated by hypoxia. Front Biosci (Landmark Ed). 27:232022. View Article : Google Scholar : PubMed/NCBI